What is the current Price Target for the NLS Pharmaceutics Ltd stock?

The average NLS Pharmaceutics Ltd target price is $6.12. This is 393.55% higher than the current stock price. The highest price target is 408.06%, the lowest is 388.71%. 3 Analysts have issued a price target NLS Pharmaceutics Ltd 2026 .

How high will the NLS Pharmaceutics Ltd stock rise?

No reliable answer can be given as to how high the NLS Pharmaceutics Ltd stock will rise. The performance of stocks, including the NLS Pharmaceutics Ltd stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the NLS Pharmaceutics Ltd stock today?

The performance of NLS Pharmaceutics Ltd stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the NLS Pharmaceutics Ltd stock fall?

The decline in NLS Pharmaceutics Ltd stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

NLS Pharmaceutics Ltd Forecast, price target & analysts

$1.24

4.62% yesterday

Nasdaq, Oct 27, 09:19 pm CET

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

NLS Pharmaceutics Ltd Target price 2025 - Analyst rating & recommendation

NLS Pharmaceutics Ltd Classifications & Recommendation:

Hold

50%

Sell

50%

NLS Pharmaceutics Ltd Price Target

Target Price	$6.12
Price	$1.24
Potential	393.55% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target NLS Pharmaceutics Ltd 2026 . The average NLS Pharmaceutics Ltd target price is $6.12. This is 393.55% register free of charge higher than the current stock price. The highest price target is $6.30 408.06% register free of charge , the lowest is $6.06 388.71% register free of charge .
	A rating was issued by 6 analysts: 0 Analysts recommend NLS Pharmaceutics Ltd to buy, 3 to hold and 3 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the NLS Pharmaceutics Ltd stock has an average upside potential 2026 of 393.55% register free of charge . Most analysts recommend the NLS Pharmaceutics Ltd stock at Sell or hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-2.63	-0.46
	79.37%	82.51%
P/E		negative

3 Analysts have issued a NLS Pharmaceutics Ltd forecast for earnings per share. The average NLS Pharmaceutics Ltd EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-2.63	79.37%
2025	$-0.46 82.51% Unlock

Current	-0.65	22.59%
2025	-2.83 333.19% Unlock

NLS Pharmaceutics Ltd...

Discover more stocks with a high price target

TUI 50.52%

Deutsche Telekom 33.66%

Netflix 32.33%

Novo Nordisk 32.00%

BioNTech SE - ADR 31.77%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now